Abstract:Chronic Heart Failure (CHF) is the end result of nearly all cardiovascular disease and is the leading cause of deaths worldwide. Studies have demonstrated that intestinal flora has a close relationship with the development of Cardiovascular Disease (CVD) and plays a vital role in the disease evolution process. Phenylacetylglutamine (PAGln) a metabolite of the intestinal flora, is one of the common chronic kidney disease toxins. Its concentrations in plasma were higher in patients with major adverse cardiovascular events (MACE) however, its variation in patients with various degrees of CHF has rarely been reported. Therefore, we collected stool and plasma samples from 22 healthy controls, 29 patients with NYHA Class III and 29 patients with NYHA Class IV CHF (NYHA stands for New York Heart Association) from the Department of Cardiology of Shanghai Fengxian District Central Hospital. Next, we analyzed these samples by performing bacterial 16S ribosomal RNA gene sequencing and liquid chromatography tandem mass spectrometry. The result shows: The Chao 1 index was significantly lower in both NYHA class III and NYHA class IV than it was in the control group. The beta diversity was substantially dissimilar across the three groups. The linear discriminant analysis effect size analysis (LEfSe) showed that the bacterial species with the largest differences were Lachnospiraceae in control group, Enterobacteriaceae in NYHA class III, and Escherichia in NYHA class IV. The concentration of PAGln was significantly different between CHF and control groups and increased with the severity of heart failure. Finally, the correlation analysis represented that Parabacteroides and Bacteroides were negatively correlated to brain natriuretic peptide (BNP) and PAGln; Romboutsia and Blautia adversely associated with PAGln; Klebsiella was positively interrelated with BNP; Escherichia-Shigella was positively correlated with PAGln and BNP; Alistipes was contrasted with BNP; and Parabacteroides was negatively correlated with the left ventricular end-diastolic diameter (LVEDD). This study presented that the intestinal flora and its metabolite PAGln were altered with different grades of CHF and illustrated the effects of the gut flora and its metabolite on CHF.

Role of the Gut Bacteria-Derived Metabolite Phenylacetylglutamine in Health and Diseases

A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors

Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights

Gut microbe-generated phenylacetylglutamine is an endogenous allosteric modulator of β2-adrenergic receptors

Two distinct gut microbial pathways contribute to meta-organismal production of phenylacetylglutamine with links to cardiovascular disease

Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure

Gut-Microbiota-Related Metabolite Phenylacetylglutamine and Risk of Incident Coronary Heart Disease among Women

Gut microbiota-derived metabolites and their importance in neurological disorders

Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases

Neuroprotection by agmatine: Possible involvement of the gut microbiome?

Abstract 11851: Acetate Rescues the Gut Microbial Metabolites PAA/PAG-induced Vascular Senescence by Epigenetic and SASP Regulation

Gut commensals and their metabolites in health and disease

The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease

The Gut Microbial Bile Acid Modulation and its Relevance to Digestive Health and Diseases

Dysbiosis of Gut Microbiota and Metabolite Phenylacetylglutamine in Coronary Artery Disease Patients With Stent Stenosis

Phenylacetyl Glutamine (pagln) Enhances Cardiomyocyte Death after Myocardial Infarction Through Β1 Adrenergic Receptor

Dysbiotic Gut Microbiota-Derived Metabolites and Their Role in Non-Communicable Diseases

Microbiome–metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease

Diet-induced metabolic changes of the human gut microbiome: importance of short-chain fatty acids, methylamines and indoles

Gut Microbiota Composition and Epigenetic Molecular Changes Connected to the Pathogenesis of Alzheimer's Disease

Growth effects of N-acylethanolamines on gut bacteria reflect altered bacterial abundances in inflammatory bowel disease